Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson’s disease
Abstract When short plasma half-life drugs act only briefly, they require frequent or continuous administration. We report the engineering of a non-invasive oral drug delivery system for long-term, continuous administration of these drugs. Their non-invasive, long-term, continuous administration at...
Saved in:
| Main Authors: | William L. Murch, John Spiridigliozzi, Adam Heller, Ephraim Heller |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-78145-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01) -
USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01) -
Direct Initiation of Levodopa–Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease
by: Vili Viljaharju, et al.
Published: (2024-12-01) -
How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
by: Robert A. Hauser, et al.
Published: (2025-01-01) -
Carbidopa/levodopa dose elevation and safety concerns in Parkinson's patients: a cross-sectional and cohort design
by: Michael S Okun, et al.
Published: (2012-12-01)